Projecting future drug expenditures--1998

• Published in: American journal of health-system pharmacy 1998-01, Vol.55 (2), p.127-136
• Main Authors: Mehl, B, Santell, JP
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Drug Approval; Drug Costs - statistics & numerical data; Drug Costs - trends; Drug Industry - economics; Drug Prescriptions - economics; Drug Utilization - economics; Drug Utilization - statistics & numerical data; Drug Utilization - trends; Drugs, Investigational; Economics, Pharmaceutical - statistics & numerical data; Economics, Pharmaceutical - trends; Formularies as Topic; General aspects; Health systems. Social services; Humans; Medical sciences; Public health. Hygiene; Public health. Hygiene-occupational medicine; United States; United States Food and Drug Administration
• ISSN: 1079-2082; 1535-2900
• DOI: 10.1093/ajhp/55.2.127

Drug cost projections for 1998, factors that directly influence drug costs, and tools for projecting drug expenditures are discussed. The producer price index indicates that prices for drugs and pharmaceuticals increased 2.1% between January and June 1997; the increase for prescription preparations was 2.7%. Medi-Span data show an average increase for all drug products of 1.02% during the first six months of 1997; First Data-Bank reports a 1.7% increase for the same period. IMS America data, which take account of weighting for individual drugs or drug classes, show the prices of all drugs increasing 2.3% between the second quarters of 1996 and 1997. Drug industry analysts project the overall price increase in the next 12 months at 2-4%. Group purchasing organizations predict an average increase over the next 12 months of 0.56% for contracted drugs and 3.6% for noncontracted drugs. Various health care provider indexes suggest that increases in drug costs could be smaller over the next few years. The current trend of takeovers and mergers of pharmaceutical companies and health systems is likely to continue into 1998. As a result of generic competition and the loss of patent protection for many pharmaceutical products, the number of drugs to be introduced onto the market and the number of drugs in development are expected to escalate until the year 2000. These and other major changes in the health care environment, including changes in drug distribution and controversies over the use of formularies, will make future forecasting difficult. Compared with previous years, smaller increases in drug costs have been projected for 1998 and beyond, but changes in the health care environment mean that greater knowledge will be required to forecast future drug expenditures.